Signed in as:
filler@godaddy.com
Exodus New Ventures is targeting unmet needs in musculoskeletal and soft tissue repair with minimally invasive and bioresorbable implants, wearables, surgical navigation, machine learning and artificial intelligence. The founders of Exodus New Ventures have helped create and lead over 18 successful startups in medical device with over $1B returned to investors.
MDLifespan is a fast-growing, revenue generating company targeting the $30B U.S. detoxification and toxin-removal market with its proprietary protocols in Therapeutic Plasma Exchange (“TPE”), which studies have shown to be 300% more effective at removing toxins, microplastics, heavy metals, mold and spike proteins from the body. The Company’s mission is to eliminate environmental toxins from the human body through innovative, physician-led protocols — reducing disease, chronic inflammation, and raising public awareness of the existential threat toxins pose to humanity.
Organamet Bio is revolutionizing heart failure treatment by developing a pipeline and deep scientific bench of personalized, bioengineered products for the two most prevalent forms of disease: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). From biologics (Lami-Pro™) to regenerative patches (Ventri-Pro™) to fully vascularized personalized bioengineered hearts (Your-Heart™), Organamet Bio offers innovative, patient-specific treatments for millions of people. Click here for a brief video overview.
Liife's AI-driven eligibility and Identification Verification Management (IVM) solution modernizes Medicaid/Medicare processing, preventing waste, fraud, and abuse saving billions annually while ensuring compliance and operational efficiency. The Company is pioneering a $50B market and has assembled an experienced team consisting of innovators in the cybersecurity and healthcare finance industry, as well as legislators and strategic institutions.
PolyXLabs is a biotechnology company pioneering a new class of sustainable and naturally derived polymers that are lightweight, durable, free of toxic chemicals and other harmful containments, and release no microplastics during their lifecycle. Recently acquired and now part of Tempra Technologies.
Vivaera is a privately held, revenue generating biotech and nanotechnology company developing novel therapeutics to address oncology, neurodegenerative diseases and diabetes, addressing a $500B+ segment of healthcare. The Company collects and analyses data through a mix of proprietary patient centric methods. This results in custom compounds developed at the nano level that address the root cause to a host of debilitating diseases without causing harm to the patient, and at an affordable price.
Swaza engineers revolutionary nanotherapeutics, disrupting a $56B US market by creating scalable, life-saving solutions for patients with critical respiratory conditions. The company has received awards and engagements from J&J, U.S. Health & Human Services, and NATO for its self-stable product that can easily be administered in the field via a simple nebulizer disrupting the need for ventilators and oxygen tanks.
TrueRelief is a medical device company that has developed an FDA-cleared, noninvasive, non-opioid, portable, neuromodulation device with 13 issued patents and over 18,000 successful treatments. The technology safely and effectively delivers pulsed direct current at 20,000 Hz, which the patient cannot feel that reduces inflammation, pain, and rapidly accelerates healing while decreasing, and in many cases eliminating, the need for opioids, and in as little as three 10-minute treatment sessions.
HopFlyt is an innovative aerospace company focused on advancing aviation through the development of next-generation electric and hybrid-electric Vertical Takeoff and Landing (eVTOL) aircraft for both civilian and defense markets. HopFlyt’s patented Channel Wing Propulsion System™ significantly enhances efficiency and performance, positioning HopFlyt to capitalize on the rapidly expanding Advanced Air Mobility (AAM) market, which is expected to reach a TAM of $1 trillion by 2040.
Hipstr is a B2B and B2C SaaS event service platform poised to disrupt the events, media, and experiential marketing industry by streamlining the process of creating user generated content at in person events. The company is on track to become the leading marketplace and proprietary platform for media and event services, with an existing footprint in 30 major US markets, over 1,000 five-star reviews, and a customer list that includes Disney, Google, Coach, Sony, MLB, NFL, and other major brands.
Algas Panameñas is a Panama-based leader in supplying all-natural animal feed ingredients and other environmentally healthy products produced by converting large amounts of saltwater and carbon into tropical seaweed.
RePlastic Recycle is revolutionizing the plastic problem with a holistic approach that incorporates their AI-driven RPR System (RPRS). Their proprietary solution includes a cost effective, transportable, turn-key modular system that captures, cleans, and processes plastic waste. The result is a visually appealing medium that is then fabricated locally into useful quality products, including building materials, furniture, all weather items like planter boxes and signs, or even art and souvenirs. The RPR System transforms waste into a valuable material that can be used locally, creating jobs, and providing an environmentally responsible and financially sustainable true circular economy solution to a multi-billion-dollar problem.
The Storm Guys is a leading auto hail repair company that is transforming the industry with AI and advanced methods resulting in high quality repairs with fast, friendly, concierge style service.
Purim Ventures has brought multiple leading-edge technologies to the 170+ VA system, including orthopedic implants, biologics, non-narcotic pain management technologies, advanced imaging, and wearables. Through established relationships with leading veteran channel partners, innovative companies have been able to accelerate their go-to-market and reach some of our most deserving patients.
